Introduction
============

Cardiovascular diseases remain some of the most prevalent health challenges today. Predominant among these, atherosclerosis and resultant ischemic heart disease, stroke, and peripheral artery disease are estimated to cause 8.9 million deaths per year, making it the single most significant cause of death worldwide ([@B103]). We and others have reported that hyperlipidemia, together with other CVD risk factors, such as hyperglycemia, chronic kidney disease, obesity, and hyperhomocysteinemia (HHcy), promotes atherosclerosis development via several mechanisms. These mechanisms include endothelial cell (EC) activation and injury ([@B87]; [@B118]; [@B61], [@B59]); monocyte recruitment and differentiation ([@B21]; [@B32]); decreased function of regulatory T cells (Tregs) ([@B3]; [@B114]; [@B58]); transdifferentiation of Tregs into antigen-presenting cell (APC) like Tregs ([@B111]); impaired vascular repairability of bone marrow-derived progenitor cells ([@B29]; [@B8]; [@B62]); increased migration and proliferation of vascular smooth muscle cells ([@B70]; [@B33]), and high fat-induced adipocyte hypertrophy and metabolic healthy obesity ([@B99]). Human aortic endothelial cell (HAEC) activation is widely understood to contribute substantively to the early development of atherosclerosis by increasing leukocyte recruitment through upregulation of adhesion molecules such as ICAM1 ([@B94]; [@B98]; [@B35]). We have recently reported that exposure to proatherogenic stimuli, such as the proinflammatory lysophospholipid lysophosphatidylcholine (LPC), can induce prolonged HAEC activation as part of early atherogenesis ([@B61],[@B63], [@B60]); this phenomenon is one of a larger class of conditional danger-associated molecular patterns (DAMPs) that trigger the onset of oxidative, autoimmune, and inflammatory tissue damages ([@B104]; [@B88]). However, the regulatory mechanisms underpinning these physiological changes remain poorly understood; and whether and how non-coding RNAs (ncRNAs) mechanisms control HAEC activation remains poorly characterized.

For many years, proteins have represented the primary functional end product of genetic information, though the genes that encode them account for less than 2% of the genome ([@B5]). As new sequencing technology advances, as many as six types of ncRNAs have been identified, including three small ncRNA types \[i.e., RNA interference (RNAi), tRNA-derived stress-induced RNA (tiRNA), and small nuclear RNA (snRNA)\] and three long RNAs types \[i.e., transfer RNA (tRNA), ribosomal RNA (rRNA), and long non-coding RNAs (lncRNA)\] ([@B36]). RNAi can be categorized into five subgroups including small interfering RNA (siRNA), piwi-interacting RNA (piRNA), and microRNA (miRNA), repeat associated siRNA (rasiRNA), and agotron. LncRNAs can be further classified into six subtypes: sense lncRNA, intronic lncRNA, antisense lncRNA, intergenic lncRNA, enhancer RNA (eRNA), and circular RNA (circRNA). These ncRNAs together constitute almost 60% of the transcriptional output in human cells, and they have been shown to regulate cellular processes and pathways in developmental and pathological contexts through mRNA degradation or modification, transcription regulation, translation regulation, and miRNA sponging, among other functions ([@B68]; [@B10]; [@B18]; [@B54]). We previously reported that a group of anti-atherogenic miRNAs might suppress proatherogenic gene expression ([@B100], [@B101]; [@B67]). We also found that microRNA-155 (miR155) is among several miRs significantly upregulated in atherogenic apolipoprotein E deficient (ApoE-/-) mouse aortas. MiR155 promotes HAEC activation and mouse atherosclerosis, whereas the deficiency of miR155 in ApoE-/- background leads to high fat-induced adipocyte hypertrophy and establishes a novel metabolically healthy obese (MHO) mouse model ([@B99]). Among 109 miRNAs that we examined in all four hyperlipidemia-related diseases (HRDs), namely atherosclerosis, non-alcoholic fatty liver disease (NAFLD), obesity and type II diabetes (T2DM), miR-155 and miR-221 are significantly modulated in these HRDs. MiR-155 is significantly upregulated in atherosclerosis and decreased in other HRDs. MiR-221 is increased in three HRDs but reduced in obesity. These findings led to our new classification of types I and II MHOs, which are regulated by miR-221 and miR-155, respectively. We also found that the proinflammatory adipokine, resistin, is significantly increased in white adipose tissues (WAT) of the MHO mice, revealing our newly proposed, miR-155-suppressed "secondary wave inflammatory state (SWIS)," characteristic of MHO transition to classical obesity (CO) ([@B47]). Our and others' results demonstrate that ncRNAs play significant roles in regulating the pathogenesis and progression of cardiovascular diseases and other diseases.

Two types of lncRNAs (i.e., linear and circular forms) have been found in the lncRNA family. In contrast to previous models, recent work has shown that circRNAs are relatively abundant and may be the predominant transcripts of hundreds of genes. The spliceosome machinery produces circRNAs by direct back-splicing of exons or introns within pre-mRNA or by exon skipping. As a result of a direct back-splicing event, an exon is not associated with an adjacent downstream exon, as seen in linear splicing, but with an upstream exon or intron. This back-splicing gives rise to circular RNA molecules harboring exons or introns that are out-of-order from the genomic context ([Figure 1A](#F1){ref-type="fig"}). These circular molecules are ubiquitously expressed in human and more than 30,000 different circRNAs have been identified. They are regulated in several disease states and contribute to disease development and progression ([@B36]). Although the importance of circRNAs in regulating EC function has been reported, the comprehensive analyses of circRNAs in EC activation, EC function, and cardiovascular diseases remain at their infancy; additionally, the characterization of circRNAs in atherosclerosis-relevant HAECs has not been reported ([@B66]; [@B43]; [@B85]).

![**(A)** Lysophosphatidylcholine (LPC)-induced top 5% significantly changed circular RNAs (circRNAs) are studied in human aortic endothelial cells (HAECs) in comparison to that of control HAECS. This is a flow chart to outline how we analyzed the 5% top significantly changed circular RNAs from LPC-treated HAECs in comparison to that from control HAECs. **(B)** The majority (48 out of 51,94.1%) of circRNA expression increases while related mRNA expressions remain constant or decrease. **(C)** There is no significant differences in exon numbers among circRNA groups. **(D)** There are no overlaps among the top 10 pathways in the following four groups.](fphys-10-00433-g001){#F1}

Regardless of the progress, we identified several important knowledge gaps to be filled in this study. We hypothesized that circRNAs might play an important role in mediating homeostatic status in HAECs activated by proatherogenic LPC. We analyzed our RNA-Seq raw data sets, obtained from control-, and LPC- treated HAECs ([@B60]), using two well-accepted circular RNA databases such as CircExplorer2 and CIRI to obtain a list of significantly changed circular RNAs (circRNAs) ([@B34]; [@B122]) 4. We found that this list of 77 circRNAs may play homeostatic roles in activated HAECs via novel mechanisms including exon usage competition, miRNA sponging ([@B37]; [@B69]) and potential generation of short proteins for protein interaction disruption. We also found that novel mechanisms, such as (a) flanking intron homology, (b) LPC-induced modulation of spliceosome components, and (c) upstream chromatin long-range interaction, play important roles in promoting the generation of circRNAs in LPC-activated HAECs. These novel insights may lead to the identification of new therapeutic targets for treating metabolic cardiovascular diseases, inflammations, and cancers.

Materials and Methods {#s1}
=====================

Generation of CircRNA Datasets
------------------------------

Raw RNA-Seq data was obtained from a previous study ([@B60]). Raw reads generated by the Illumina HiSeq control software were assessed using FastQC ([@B6]). Samples with poor sequence quality were discarded. Sequence reads were mapped to the hg38 genome using STAR ([@B26]). Fusion junction reads were parsed using CIRCexplorer2 and captured back-splicing junction reads were then annotated with UCSC annotation files ([@B122]). For additional detections, sequence reads were mapped to the hg38 genome using the Burrows-Wheeler Alignment tool ([@B57]), circRNAs were identified using CIRI ([@B34]). Gene annotation was performed using org.Hs.eg.db ([@B16]). A list of circRNAs common to both control and LPC-stimulated HAECs was generated using the VLOOKUP function in Microsoft Excel. To filter out significantly changed circRNAs, ratios of control to LPC-stimulated circRNA read numbers were calculated, and base 2 logarithms taken of these ratios. Mean and standard deviation of logarithm values were calculated using MATLAB and used to generate a 95% confidence interval (mean ± 2^∗^SD). Using previously obtained mRNA expression data ([@B60]), an mRNA fold change confidence interval was similarly calculated using the ten housekeeping genes: C1orf43, CHMP2A, GAPDH, EMC7, GPI, PSMB2, PSMB4, RAB7A, SNRPD3, and VPS29; and it was used to separate circRNAs by corresponding mRNA expression change.

Comparison of Flanking Intron Sequences
---------------------------------------

The generated circRNA data included flanking intron coordinates; a Python script was used to parse these coordinates and feed them into an NIH NCBI BLAST+ command line query (blastn -max_hsps 1 -outfmt "10 pident *e*-Value bitscore") comparing the sequences of 3′ and 5′ flanking intron sequences using local copies of hg38 human genome primary assembly chromosome sequences^[1](#fn01){ref-type="fn"}^ ([@B15]). This returned percent identity, the expected value (number of matches of equal strength expected by chance), and bitscore values (normalized score for match strength) for each pair of flanking introns. These were then exported to a text file and imported into a Microsoft Excel spreadsheet for tabulation. Bitscore values were further used for statistical analysis (described below under "Statistical Analysis").

Matching CircRNAs to Database Entries
-------------------------------------

The genomic length of each significantly changed circRNA was calculated by subtracting its genomic start coordinate from its genomic end coordinate. A MATLAB script was then used to find circRNAs with matching length and gene locus from a local copy of the circRNAdb database and to export all results to a Microsoft Excel spreadsheet ([@B83]; [@B20]). Notably, genomic coordinates in circRNAdb were given with respect to the older hg37 human genomic annotation. A local copy of the hg37 genomic annotation was therefore obtained for comparison^[2](#fn02){ref-type="fn"}^. Then, NIH NCBI BLAST+ queries between original hg38 coordinates and CircRNAdb hg37 coordinates (blastn -max_hsps 1 -outfmt "10 pident") were performed using a MATLAB script ([@B83]; [@B15]), taking only the single best match for each pair of sequences, the percent identity values of which confirmed sequence alignment for all length matches found. CircInteractome also uses the hg37 human genome annotation but a different set of IDs; matches in CircInteractome were determined by hand due to incomplete downloadable data sets.

Analysis of Long--Range Interactions
------------------------------------

A complete list of long--range chromatin interaction sites in the human genome was obtained from the 4DGenome database^[3](#fn03){ref-type="fn"}^ as a tabulated text file ([@B97]). The grep command line utility was used to filter for entries detected using Hi-C methodology and involving at least one circRNA-related gene. The resulting filtered data was imported into Microsoft Excel and raw interaction distances calculated as the differences between gene start coordinates. An AWK script was used to determine whether the circRNA-related gene was downstream or upstream of its partner in each interaction pair and to add this information to the data file. The signs of distance values were then updated, with downstream entries designated as positive and upstream values designated as negative, using a Python script. These updated distance values were separated into the same six groups as their corresponding circRNA-related genes and used in pairwise two-sample Kolmogorov--Smirnov tests (described further below under "Statistical Analysis"). Distance distributions for all upregulated and all downregulated circRNAs were compared by groups overall as well as by only upregulated and downregulated circRNAs with increased, unchanged, or decreased corresponding mRNA expression, respectively.

Characterizing Open Reading Frame Sequences
-------------------------------------------

Open reading frame (ORF) peptide sequences and internal ribosomal entry site (IRES) data were obtained to identify significantly changed circRNAs from circRNAdb ([@B20]). A MATLAB script was used to call remote NIH NCBI BLAST+ peptide alignments for all ORF sequences against the NCBI non-redundant protein sequences database (nr^[4](#fn04){ref-type="fn"}^) ([@B83]; [@B15]), restricted to entries for *Homo sapiens* (blastp -db nr -remote -entrez_query "Homo sapiens \[Organism\]" -max_target_seqs 1 -outfmt "10 sacc pident *e*-Value"). This returned the subject accession, percent identity, and expected value of the single best database match, which was then exported with the gene name and circRNAdb ID to a Microsoft Excel spreadsheet. The obtained accessions were individually and manually searched on the NCBI protein database^[5](#fn05){ref-type="fn"}^ to determine if they corresponded to canonical mRNA transcripts from the same gene locus as the corresponding circRNA. A modified version of the hg38/hg37 comparison MATLAB script was also used to run NIH NCBI BLAST+ searches for the Kozak consensus sequence gccRccAUGG in genomic sequences of all significantly changed circRNAs ([@B51]; [@B83]; [@B15]).

Pathway Analysis
----------------

QIAGEN Ingenuity Pathway Analysis (IPA) software, which constructs predicted upstream and downstream causal networks for input datasets from a curated research literature base, was used to elucidate potential downstream pathways for sponged miRNAs ([@B53]). Lists of miRNAs were input into IPA and ran through the miRNA target filter to generate a list of potential mRNA targets. The list of mRNA target genes was then run through an IPA core analysis. All canonical downstream pathways returned in the resulting output were exported into a Microsoft Excel spreadsheet. The top ten pathways were extracted for further qualitative consideration.

Graphical Figure Generation
---------------------------

For three-group Venn diagrams, lists of genes were input into an online Venn diagram generator (^[6](#fn06){ref-type="fn"}^Evolutionary Genomics, Ghent University, Gent, Belgium) (Draw Venn Diagram). This tool was used to produce both diagrams and lists of overlapped genes between groups. For six-group Venn diagrams, gene lists were input into the InteractiVenn online tool^[7](#fn07){ref-type="fn"}^ to generate diagrams ([@B39]), while the above Ghent University tool was again used to produce lists of overlapped genes between groups (Draw Venn Diagram). Explanatory and conceptual graphics were produced using Microsoft Paint.

Statistical Analysis
--------------------

Descriptive summary statistics were reported by group. Data were checked for normality assumption and, if found to be not normally distributed, subsequently transformed using various functions such as the log10 and cubic-root to find the optimal transformation for the underlying chromatin long-range interaction distance distribution data. Chromatin long-range interaction distance density functions were then estimated and plotted by group under the optimal transformation using the non-parametric kernel density approach with a normal weight function ([@B48]; [@B41]; [@B90]). Pairwise comparisons of median chromatin long-range interaction distance among the six groups were performed with multiple comparison adjustments using the Dwass, Steel, and Critchlow-Fligner method based on the Wilcoxon test for downstream and upstream data separately ([@B28]; [@B22]; [@B41]; [@B84]). Pairwise comparisons between groups for chromatin long-range interaction distance distribution, median distance location shift, and distance distribution scale were implemented using the Kolmogorov--Smirnov two-sample test, Hodges--Lehmann estimation method and Fligner-Policello test, and Ansari-Bradley test, respectively, again for downstream and upstream data separately ([@B56]; [@B28]; [@B22]; [@B41]; [@B84]). SAS version 9.4 was used to perform these analyses and generate density function plots for the chromatin long-range interaction distance data.

For rest of the data, single-factor ANOVA and non-parametric Kruskal--Wallis tests were conducted for all multi-group analyses using the Real Statistics Resource Pack add-in for Microsoft Excel^[8](#fn08){ref-type="fn"}^ ([@B119]). For confidence intervals, MATLAB was used to calculate mean and standard deviations for data sets ([@B83]). Probabilities of ratios of upregulation to downregulation were calculated by summing binomial coefficients and dividing by the appropriate power of 2 in MATLAB ([@B83]), as given by the formula $\mathit{p} = \frac{\sum\limits_{\mathit{i} = \mathit{n}}^{\mathit{u}}\begin{pmatrix}
i \\
\mathit{u} \\
\end{pmatrix}}{2^{\mathit{u}}}$, where *u* is the total number of genes considered and *n* is the large number of upregulated or downregulated genes.

Results
=======

LPC Modulates the Expression of a List of 77 Circular RNAs in HAECs; and the Majority of Which, 94.1% of Increased CircRNAs, Compete With Related mRNAs for Exon Usage
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Our preliminary data processing detected 3,170 distinct circRNAs in control cells and 3,486 circRNAs in a proatherogenic lipid LPC-treated HAECs as we reported ([@B61]). To better analyze our data set, we derived a list of 1,093 circRNAs found in both the control and LPC-treated data sets before calculating read number ratio -- the quotient of the read number in the LPC-treated data set and the corresponding read number in the control data set -- for each circRNA in the list to serve as a measure of expression change ([Figure 1A](#F1){ref-type="fig"}). We then took the base-2 logarithm of each readnumber ratio (log ratio) and calculated a 95 percent confidence interval (-0.3815 ± 2.3395) for log ratio, taking all the 77 circRNAs with log ratios outside this confidence interval to have significantly changed levels of expression in LPC-treated HAECs ([Table 1A](#T1a){ref-type="table"}). Then, we separated these circRNAs into two groups of increased and decreased circRNA expression. To assess potential relationships between circRNAs and their corresponding mRNAs published, we then further divided each of these groups into three subgroups based on increased, unchanged, or decreased expression of corresponding mRNA transcripts, with all fold change levels within a 95 percent confidence interval (1.01 ± 0.1) determined by the housekeeping genes C1orf43, CHMP2A, GAPDH, EMC7, GPI, PSMB2, PSMB4, RAB7A, SNRPD3, and VPS29 considered to indicate unchanged mRNA expression ([Table 1B](#T1b){ref-type="table"}), thereby obtaining six groups of significantly changed circRNAs classified by changes in both circRNA and corresponding mRNA expression.

###### 

LPC-induced 77 circRNAs in HAECs can be classified into 6 groups based on expression change of circRNAs and corresponding (related) mRNAs.

  Gene ID                                                             Gene            circRNAdb ID     Readnumber (LPC)   Readnumber (Control)   Ratio    Log(2) ratio   FC (mRNA)   Index (circRNA exons)                                         Exon count   Exon count (genomic)
  ------------------------------------------------------------------- --------------- ---------------- ------------------ ---------------------- -------- -------------- ----------- ------------------------------------------------------------- ------------ ----------------------
  circRNA expression increased, mRNA expression increased ([@B87])                                                                                                                                                                                              
  23094                                                               SIPA1L3         hsa_circ_10577     9                  2                      4.5      2.17         1.12        11,12                                                           2          24
  117583                                                              PARD3B          N/A                4                  1                      4        2            1.19        4,5,6,7,8,9,10,11, 12,13,14,15                                12           33
  116840                                                              CNTROB          hsa_circ_09218     4                  1                      4        2            1.11        13                                                              1          22
  circRNA expression decreased, mRNA expression increased ([@B61])                                                                                                                                                                                              
  2530                                                                FUT8            hsa_circ_02544     1                  7                      0.14   --2.81         1.2         3                                                               1          15
  768211                                                              RELL1           hsa_circ_08846     2                15                       0.13   --2.91         1.15        6,5,4                                                           3            8
    51150                                                               SDF4          hsa_circ_21644     1                  9                      0.11   --3.17         1.15        4,3                                                             2            8
  64778                                                               FNDC3B          hsa_circ_15231     1                15                       0.07   --3.91         1.13        5,6                                                             2          30
  circRNA expression increased, mRNA expression unchanged ([@B43])                                                                                                                                                                                              
  55852                                                               TEX2            hsa_circ_31354   15                   1                    15         3.91         0.98        7,6,5                                                           3          15
  5820                                                                PVT1            hsa_circ_16350     8                  1                      8        3                          2                                                             1            9
  51232                                                               CRIM1           hsa_circ_16396   15                   2                      7.5      2.91         1.03        2,3,4                                                           3          22
  1793                                                                DOCK1           hsa_circ_00689     7                  1                      7        2.81         1.05        2,3,4,5,6,7,8,9,10,11, 12,13,14,15,16,17, 18,19,20,21,22,23   22           56
  4670                                                                HNRNPM          hsa_circ_20744     7                  1                      7        2.81         1.01        2,3,4,5                                                         4          16
  22937                                                               SCAP            hsa_circ_19380     7                  1                      7        2.81         0.94        8,7,6,5,4                                                       5          25
  9341                                                                VAMP3           hsa_circ_18051     7                  1                      7        2.81         0.94        3,4                                                             2            5
  N/A                                                                 RP11-146B14.1   N/A                6                  1                      6        2.58         \#N/A       12,13,14,15                                                     4          
  9380                                                                GRHPR           hsa_circ_03935     6                  1                      6        2.58         1.06        2,3,4                                                           3          11
  27086                                                               FOXP1           hsa_circ_19469     6                  1                      6        2.58         1.01        12,11,10,9,8                                                    5          32
  64750                                                               SMURF2          hsa_circ_01208     5                  1                      5        2.32         1.11        10,9,8,7,6                                                      5          19
  84456                                                               L3MBTL3         N/A                5                  1                      5        2.32         1.03        4,5,6,7,8,9,10,11, 12,13,14,15,16, 17,18,19,20,21             18           30
  862                                                                 RUNX1T1         N/A                5                  1                      5        2.32         0.99        5,4,3,2                                                         4          20
  151050                                                              KANSL1L         hsa_circ_06859     5                  1                      5        2.32         0.96        4,3,2                                                           3          23
  11138                                                               TBC1D8          hsa_circ_32540     5                  1                      5        2.32         0.94        15,14,13,12,11,10                                               6          25
  84328                                                               LZIC            hsa_circ_31394     5                  1                      5        2.32         0.94        4,3,2                                                           3          10
  23331                                                               TTC28           hsa_circ_22261     5                  1                      5        2.32         0.93        3,2                                                             2          29
  1456                                                                CSNK1G3         hsa_circ_08140   14                   3                      4.67     2.22         0.93        2,3,4                                                           3          18
  8460                                                                TPST1           hsa_circ_22617     9                  2                      4.5      2.17         0.98        2,3                                                             2            8
  \#N/A                                                               PRKY            hsa_circ_30664     4                  1                      4        2            N/A         4,5,6,7                                                         4            8
  \#N/A                                                               PCNXL2          hsa_circ_10712     4                  1                      4        2            N/A         23,22                                                           2          
  1523                                                                CUX1            hsa_circ_12403     8                  2                      4        2            1.11        21                                                              1          34
  9701                                                                PPP6R2          hsa_circ_07544     4                  1                      4        2            1.11        2,3                                                             2          29
  54919                                                               DNAAF5          N/A                4                  1                      4        2            1.1         9,10,11                                                         3          14
  84293                                                               FAM213A         N/A                4                  1                      4        2            1.06        2,3,4                                                           3            9
  7813                                                                EVI5            hsa_circ_11187     4                  1                      4        2            1.04        19,18,17                                                        3          30
  81608                                                               FIP1L1          hsa_circ_18069     4                  1                      4        2            1.02        11,12,13                                                        3          19
  51295                                                               ECSIT           hsa_circ_00599     4                  1                      4        2              1         4,3                                                             2            9
  152002                                                              XXYLT1          hsa_circ_02143     4                  1                      4        2              1         3,2                                                             2          11
  6310                                                                ATXN1           hsa_circ_13397     4                  1                      4        2            0.99        8                                                               1          11
  1024                                                                CDK8            hsa_circ_27078     4                  1                      4        2            0.98        10,11,12                                                        3          14
  6259                                                                RYK             hsa_circ_26048     4                  1                      4        2            0.98        13,12,11,10,9,8,7                                               7          15
  92                                                                  ACVR2A          hsa_circ_04751     4                  1                      4        2            0.98        2,3,4                                                           3          12
  22828                                                               SCAF8           hsa_circ_06913     4                  1                      4        2            0.98        2,3,4,5,6                                                       5          22
  29086                                                               BABAM1          hsa_circ_04303     4                  1                      4        2            0.96        7,8                                                             2            9
  23244                                                               PDS5A           hsa_circ_29001     4                  1                      4        2            0.95        21,20,19,18,17                                                  5          36
  7443                                                                VRK1            hsa_circ_08594     4                  1                      4        2            0.94        2,3,4,5,6,7,8,9,10,11                                         10           15
  8826                                                                IQGAP1          hsa_circ_10932     4                  1                      4        2            0.93        6,7,8,9                                                         4          39
  circRNA expression decreased, mRNA expression unchanged ([@B62])                                                                                                                                                                                              
  23362                                                               PSD3            hsa_circ_02851   1                    7                      0.14   --2.81         1.05        8,7,6,5                                                         4          29
  55833                                                               UBAP2           hsa_circ_30156     1                  7                      0.14   --2.81         0.94        12,11,10,9                                                      4          30
  10443                                                               N4BP2L2         hsa_circ_12240     1                  7                      0.14   --2.81         0.93        6,5,4,3                                                         4          22
  6904                                                                TBCD            hsa_circ_00754     2                15                       0.13   --2.91         1.05        14,15,16,17,18,19                                               6          61
  5747                                                                PTK2            hsa_circ_23485     2                15                       0.13   --2.91         1.03        5,4,3                                                           3          44
  23603                                                               CORO1C          hsa_circ_01619     1                  9                      0.11   --3.17         1.06        8,7                                                             2          20
  5917                                                                RARS            hsa_circ_21209     1                  9                      0.11   --3.17         1.01        2,3,4,5                                                         4          15
  11174                                                               ADAMTS6         hsa_circ_28538     3                29                       0.1    --3.27         1.05        7,6,5,4,3,2                                                     6          33
  22955                                                               SCMH1           hsa_circ_12377     1                10                       0.1    --3.32         1.09        10,9                                                            2          22
  51306                                                               FAM13B          hsa_circ_11413     1                10                       0.1    --3.32         1.01        10,9,8                                                          3          30
  2050                                                                EPHB4           hsa_circ_08510     1                10                       0.1    --3.32           1         12,11                                                           2          17
  444                                                                 ASPH            hsa_circ_10828     1                11                       0.09   --3.46           1         3,2                                                             2          33
  57488                                                               ESYT2           hsa_circ_25060     1                11                       0.09   --3.46         0.95        13,12,11,10,9                                                   5          26
  10905                                                               MAN1A2          hsa_circ_02643     1                15                       0.07   --3.91         1.06        2,3,4,5                                                         4          14
  50807                                                               ASAP1           hsa_circ_09642     1                15                       0.07   --3.91         0.93        14,13,12,11,10,9                                                6          37
  circRNA expression increased, mRNA expression decreased ([@B114])                                                                                                                                                                                             
  4649                                                                MYO9A           N/A              8                    1                      8        3            0.75        39,38,37,36,35,34, 33,32,31,30,29,28                          12           48
  10564                                                               ARFGEF2         N/A                5                  1                      5        2.32         0.91        5,6,7                                                           3          39
  51444                                                               RNF138          hsa_circ_01057     5                  1                      5        2.32         0.9         3,4                                                             2            8
  152006                                                              RNF38           hsa_circ_32756     5                  1                      5        2.32         0.79        4,3                                                             2          19
  23047                                                               PDS5B           hsa_circ_01546     4                  1                      4        2            0.91        2,3                                                             2          38
  55719                                                               SLF2            N/A                4                  1                      4        2            0.9         5,6                                                             2          21
  55247                                                               NEIL3           hsa_circ_00262     4                  1                      4        2            0.84        8,9                                                             2          10
  56886                                                               UGGT1           N/A                4                  1                      4        2            0.78        2,3,4,5,6,7,8,9,10, 11,12,13,14,15,16                         15           44
  23499                                                               MACF1           N/A                4                  1                      4        2            0.68        42,43,44,45,46,47, 48,49,50,51,52                             11           111
  11123                                                               RCAN3           hsa_circ_22201     4                  1                      4        2            0.67        2                                                               1            7
  circRNA expression decreased, mRNA expression decreased ([@B21])                                                                                                                                                                                              
  659                                                                 BMPR2           hsa_circ_06837   1                    7                      0.14   --2.81         0.84        2,3                                                             2          13
  23253                                                               ANKRD12         hsa_circ_31497     1                  7                      0.14   --2.81         0.78        2,3,4,5,6,7                                                     6          18
  10725                                                               NFAT5           hsa_circ_16704     1                  8                      0.13   --3            0.64        15                                                              1          19
  26057                                                               ANKRD17         hsa_circ_01636     1                  9                      0.11   --3.17         0.91        29                                                              1          37
  55125                                                               CEP192          hsa_circ_26363     1                  9                      0.11   --3.17         0.85        2,3,4,5,6,7,8,9                                                 8          46
  121512                                                              FGD4            hsa_circ_21030     1                  9                      0.11   --3.17         0.85        5,6,7,8,9,10                                                    6          27
  22836                                                               RHOBTB3         hsa_circ_19124     1                17                       0.06   --4.09         0.91        6,7                                                             2          14
                                                                                                                                                                                                                                                                

###### 

LysoPC does not significantly modulate the expressions of housekeeping mRNAs in human aortic endothelial cells (HAECs), suggesting that the RNA-Seq experiments in HAECs treated with lysoPC were well performed.

  -------------------- -------------
  Housekeeping genes   Fold change
                       
  C1orf43                0.97
  CHMP2A                 1
  GADPH                  1
  EMC7                   0.98
  GPI                    1
  PSMB2                  0.98
  PSMB4                 1.02
  RAB7A                  0.98
  SNRPD3                 1
  VPS29                  1.04
                       
  -------------------- -------------

We also matched each circRNA, if possible, with its corresponding ID in the circRNA database CircRNAdb ([@B20]), to provide for more consistent identification, and for later analysis of the database's open reading frame data. Of note, among 51 circRNAs increased, 48 out of 51 related mRNAs (94.1%) are either unchanged (38 out of 51, 74.5%) or decreased (10 out of 51, 19.5%), while only three increased both mRNA and circRNA expression (5.9%, [Figure 1B](#F1){ref-type="fig"}). Similarly, among 26 circRNAs decreased, 19 out of 26 related mRNAs (73.1%) are either unchanged (15 out of 26, 57.7%) or increased (4 out of 26, 15.4%), while only seven decreased both mRNA and circRNA expression (26.9%, [Figure 1B](#F1){ref-type="fig"}). The results suggest that a dominant inversely correlative relationship between circRNA expression and mRNA expression levels potentially indicates exon usage competition during splicing for either circRNA expression or mRNA expression.

We also compared the average number of exons per circRNA transcript of each group using single-factor ANOVA to assess any potential impact of circRNA length on expression patterns, but no significant differences were found (*p* = 0.788) ([Figure 1C](#F1){ref-type="fig"}). Considering the slightly right-skewed distributions of exon numbers, we also performed a Kruskal--Wallis test of the same data, which also failed to indicate significance (*p* = 0.46309). These results suggest that transcript length has little to no role in modulating circRNA expression following LPC treatment in HAECs. Taken together, our results suggest that the proatherogenic lipid LPC induces a list of circRNAs in HAECs; and that a dominant inversely correlative relationship between circRNA and mRNA expression levels potentially indicates exon usage competition during splicing.

CircRNA-Related Genes Do Not Share Any Top Pathways With LPC-Induced mRNA Pathways; and Genes Associated With Significantly Changed CircRNAs Exhibit Little Relationship With Potential Effects of Inflammation-Related Cytokine Stimulation
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To determine the signaling pathways associated with circRNA-related genes, we performed the IPA. As shown in [Table 1C](#T1c){ref-type="table"}, we found the following: *first*, six top pathways related to the unchanged genes which related circRNAs were increased, including pyridoxal 5′-phosphate salvage pathway, Fcγ receptor-mediated phagocytosis in macrophage and monocyte, transforming growth factor-β (TGF-β) signaling, salvage pathways of pyrimidine ribonucleotides, epithelial adherens junction signaling, and Wnt/β-catenin signaling; *second*, ten top pathways related to the unchanged mRNAs which related circRNAs were decreased, including ephrin B signaling, focal adhesion kinase (FAK) signaling, axonal guidance signaling, ephrin receptor signaling, integrin signaling, interleukin-15 (IL-15) production, tRNA charging, semaphoring signaling in neurons, ephrin A signaling, and regulation of cellular mechanics by calpain protease; *third*, ten top pathways related to the unchanged RNAs which related circRNAs were increased, including pyridoxal 5′-phosphate salvage pathway, Fcγ receptor-mediated phagocytosis, TGF-β signaling, salvage pathways of pyrimidine ribonucleotides, epithelial adherens junction signaling, Wnt/β-catenin signaling, actin cytoskeleton signaling, cell cycle control of chromosomal replication, unfolded protein response, remodeling of epithelial adherens junctions; and *fourth*, ten top pathways related to the decreased mRNAs which related circRNAs were decreased, including role of osteoblasts, osteoclasts, and chondrocytes in rheumatoid arthritis, neuroinflammation signaling pathway, cardiomyocyte differentiation via bone morphogenetic protein (BMP) receptors, April mediated signaling, B cell activation factor signaling, Wnt/Ca++ pathway, netrin signaling, BMP signaling pathway, regulation of IL-2 expression in activated and anergic T lymphocytes and factors promotion of cardiogenesis in vertebrates. The Vann Diagram analysis found that no signaling pathways are overlapped among the four groups ([Figure 1D](#F1){ref-type="fig"}). The results suggest that, although we cannot determine directly circRNAs functional pathways in this LPC-induced HAEC activation, LPC-induced mRNAs-related HAEC activation pathways, that we reported ([@B60]), have no overlaps with any signaling pathways for circRNAs-related mRNAs.

###### 

There are no overlaps among the top 10 pathways in the following four groups \#, suggesting that the functions of circRNAs-related mRNAs do not participate in LPC-induced human aortic endothelial cell activation.

  Number       LPC upregulated mRNAs (promoting endothelial activation, PMID)                    CircRNA increased and mRNA unchanged genes (inflammation, PMID)
  ------------ --------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  1            Superpathway of cholesterol biosynthesis (HAEC activation, 29371247)              Pyridoxal 5′-phosphate salvage pathway (neurological pathologies, 22201923)
  2            Cholesterol biosynthesis I                                                        Fcγ Receptor-mediated phagocytosis in macrophages and monocytes (immune responses, 28117787)
  3            Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)                         TGF-β signaling (anti-inflammation, 22438968)
  4            Cholesterol biosynthesis III (via Desmosterol)                                    Salvage pathways of pyrimidine ribonucleotides (repair and inflammatory signal, 28053879)
  5            Granulocyte adhesion and diapedesis                                               Epithelial adherens junction signaling (epithelial cell migration, 30010460)
  6            Hepatic fibrosis/hepatic stellate cell activation                                 Wnt/β-catenin signaling (immune response, 25136145)
  7            Role of macrophages, fibroblasts, and endothelial Cells in rheumatoid arthritis   Actin cytoskeleton signaling (immune response, 30274167)
  8            Role of IL-17F in allergic inflammatory airway diseases                           Cell cycle control of chromosomal replication (immune response, 29908233)
  9            Agranulocyte adhesion and diapedesis                                              Unfolded protein response (inflammatory response, 30278941)
  10           p38 MAPK signaling                                                                Remodeling of epithelial adherens junctions (epithelial cell migration, 30010460)
                                                                                                 
  **Number**   **CircRNA decreased and mRNA unchanged genes**                                    **CircRNA decreased and mRNA decreased genes**
                                                                                                 
  1            Ephrin B signaling                                                                Role of osteoblasts, osteoclasts, and chondrocytes in rheumatoid arthritis
  2            FAK signaling                                                                     Neuroinflammation signaling pathway
  3            Axonal guidance signaling                                                         Cardiomyocyte differentiation via BMP receptors
  4            Ephrin receptor signaling                                                         April mediated signaling
  5            Integrin signaling                                                                B Cell activating factor signaling
  6            IL-15 production                                                                  Wnt/Ca+ pathway
  7            tRNA charging                                                                     Netrin signaling
  8            Semaphorin signaling in neurons                                                   BMP signaling pathway
  9            Ephrin A signaling                                                                Regulation of IL-2 expression in activated and anergic T lymphocytes
  10           Regulation of cellular mechanics by calpain protease                              Factors promoting cardiogenesis in vertebrates
                                                                                                 

CircRNAs may play roles in weakening the roles of related mRNAs via their roles in exon usage competition. \#Of note, there were no top ten pathways identified by the Ingenuity Pathway Analysis in three other groups in

Table 1A

.

We further hypothesized that LPC-induced circRNA expression could be positively associated with changes in gene expression under other pro-inflammatory stimuli. Thus, to compare the effects of LPC stimulation with that of prototypical inflammation-related responses, we obtained mRNA expression change data for cells stimulated with the pro-inflammatory cytokines tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), and interleukin 6 (IL-6) and the anti-inflammatory cytokines TGF-β, IL-4, and IL-10 from the database ArrayExpress ([@B13]; [@B96]; [@B7]; [@B46]; [@B49]; [@B72]; [@B79], [@B80]; [@B31]; [@B50]; [@B95]). We found all circRNA-related genes significantly changed after stimulation in each data set (not shown) and results indicate that cytokines with similar effects did not tend to regulate circRNA-related genes in similar directions, nor did pro-inflammatory and anti-inflammatory cytokines tend to regulate circRNA-related genes in opposing directions (not shown). This in turn suggests a limited or absent canonical role for circRNA-related genes in inflammatory response and fails to indicate general trends for pro- or anti-inflammatory cytokine modulation of circRNA-related genes. However, it neither supports nor disproves the roles of inflammatory signaling in regulating circRNA levels, as circRNA levels are largely independent of the mRNA expression levels used in this analysis and, furthermore, circRNAs may fulfill different physiological functions such as homeostasis than their canonically spliced mRNA counterparts do such as promotion of HAEC activation induced by LPC.

68.8% of the CircRNAs Feature Significant Flanking Intron Homology
------------------------------------------------------------------

To identify the potential mechanism underlying the generation of circRNAs, previous reports found that many circRNA transcripts feature reverse complementary flanking intron sequences, which enable self-pairing that brings 3′ and 5′ exonic sequences into close proximity, an arrangement that favors head-to-tail alternative splicing and circRNA biogenesis ([Figure 2A](#F2){ref-type="fig"}; [@B4]). To confirm this pattern in our dataset, we ran NIH NCBI BLAST sequence alignments using NIH NCBI BLAST+ command line tools (blastn -max_hsps 1 -outfmt "10 pident *e*-Value bitscore") comparing the 3′ and 5′ flanking intron sequences for each circRNA, as previously described ([@B4]). We found that 53 out of 77 circRNAs (68.8%) possessed flanking intron sequences with significant reverse complements as determined by expected value (number of matches expected given random sequences) \<1^∗^10^-20^ ([Table 2](#T2){ref-type="table"}). This number is lower than that of human 88% circRNA with the Alu repeats in flanking regions ([@B4]), and that in C. elegans circRNAs (96.3%); and high than that of Zebrafish circRNAs (2.5%) ([@B44]). To test potential association of reverse complementarity of flanking introns with different expression patterns of circRNA and mRNA, we performed a single-factor ANOVA using the bitscores (normalized values reporting strength of alignment between sequences) of circRNAs from each of the six groups sorted previously, assigning a bitscore of zero (indicating no matches better than those resulting from chance) for all circRNAs whose flanking introns did not demonstrate reverse complementarity. This initial analysis indicated significant differences between groups (*p* = 0.0011), but further inspection revealed the presence of an outstanding data point (bitscore = 4617) in the "circRNA increased, mRNA increased" group, which combined with the small size (*n* = 3) of the group greatly weakened the generalizability of the test ([Figure 2B](#F2){ref-type="fig"}). We thus performed a non-parametric Kruskal--Wallis test on the same data set, but this failed to reach significance (*p* = 0.74053). We also performed another single-factor ANOVA with the outstanding point removed, the results of which marginally failed to indicate any significant difference in bitscore between groups (*p* = 0.07877). Thus, we cannot conclude that there is an association between flanking intron homology and circRNA expression patterns, although that our statistical analysis approaches significance suggests that the area may warrant further study, especially with a larger sample. Our results indeed demonstrate that most circRNAs feature significant flanking intron homology, suggesting that this mechanism may be underlying selection for the expressions of circRNAs versus mRNAs.

![**(A)** Pre-splicing RNA transcripts with reverse complementary matches in flanking intron sequences tend to favor circRNA biogenesis, **(B)** There is no significant difference in bitscore between groups when non-parametric testing is performed.](fphys-10-00433-g002){#F2}

###### 

53 out of 77 (68.8%) circRNAs have significant homologies between flanking introns, which may facilitate chromatin looping and circRNA generation.

  Gene                                                      circRNAdb ID     \% identity   *e*-Value   Bitscore
  --------------------------------------------------------- ---------------- ------------- ----------- ----------
  circRNA expression increased, mRNA expression increased                                              
  PARD3B                                                    N/A                98.44       0.00        4617
  SIPA1L3                                                   hsa_circ_10577     90.24       0.00          374
  circRNA expression decreased, mRNA expression increased                                              
  FUT8                                                      hsa_circ_02544     93.17       0.00          429
  RELL1                                                     hsa_circ_08846     88.03       0.00          335
  FNDC3B                                                    hsa_circ_15231     84.59       0.00          311
  circRNA expression increased, mRNA expression unchanged                                              
  PCNXL2                                                    hsa_circ_10712     98.65       0.00          525
  RUNX1T1                                                   hsa_circ_02162     89.74       0.00          427
  DOCK1                                                     hsa_circ_00689     89.61       0.00          387
  TTC28                                                     hsa_circ_22261   89.6          0.00          375
  ATXN1                                                     hsa_circ_13397     89.45       0.00          300
  XXYLT1                                                    hsa_circ_02143     89.26       0.00          521
  ECSIT                                                     hsa_circ_00599     88.63       0.00          361
  CUX1                                                      hsa_circ_12403     87.25       0.00          333
  EVI5                                                      hsa_circ_11187     86.53       0.00          363
  SMURF2                                                    hsa_circ_01208     86.23       0.00          324
  IQGAP1                                                    hsa_circ_10932     86.13       0.00          291
  TEX2                                                      hsa_circ_31354     85.26       0.00          316
  TBC1D8                                                    hsa_circ_32540     84.04       0.00          263
  TPST1                                                     hsa_circ_22617     83.83       0.00          560
  LZIC                                                      hsa_circ_31394     83.55       0.00          278
  SCAF8                                                     hsa_circ_06913     83.05       0.00          261
  KANSL1L                                                   hsa_circ_06859     82.95       0.00          191
  VRK1                                                      hsa_circ_08594     82.95       0.00          115
  DNAAF5                                                    N/A                82.87       0.00          254
  PDS5A                                                     hsa_circ_29001     82.68       0.00          257
  PPP6R2                                                    hsa_circ_07544     82.34       0.00          499
  ACVR2A                                                    hsa_circ_04751     81.88       0.00          255
  VAMP3                                                     hsa_circ_18051     81.76       0.00          250
  PRKY                                                      hsa_circ_30664     81.66       0.00          230
  CSNK1G3                                                   hsa_circ_08140     80.89       0.00          226
  PVT1                                                      hsa_circ_16350     76.23       0.00          619
  circRNA expression decreased, mRNA expression unchanged                                              
  FAM13B                                                    hsa_circ_11413   89.9          0.00          379
  SCMH1                                                     hsa_circ_12377     89.74       0.00          387
  N4BP2L2                                                   hsa_circ_12240     88.45       0.00          363
  ADAMTS6                                                   hsa_circ_28538     88.41       0.00          353
  PSD3                                                      hsa_circ_02851     87.66       0.00          351
  UBAP2                                                     hsa_circ_30156     87.63       0.00          326
  PTK2                                                      hsa_circ_23485     85.49       0.00          396
  ASAP1                                                     hsa_circ_09642     84.95       0.00          294
  MAN1A2                                                    hsa_circ_02643     84.03       0.00          272
  EPHB4                                                     hsa_circ_08510     82.08       0.00          257
  circRNA expression increased, mRNA expression decreased                                              
  UGGT1                                                     N/A              87.2          0.00          326
  RNF38                                                     hsa_circ_32756     86.81       0.00          318
  RNF138                                                    hsa_circ_01057   86.3          0.00          315
  SLF2                                                      N/A                85.76       0.00          315
  RCAN3                                                     hsa_circ_22201     83.84       0.00          278
  PDS5B                                                     hsa_circ_01546     82.06       0.00          254
  circRNA expression decreased, mRNA expression decreased                                              
  RHOBTB3                                                   hsa_circ_19124     90.64       0.00          392
  ANKRD12                                                   hsa_circ_31497     85.86       0.00          313
  ANKRD17                                                   hsa_circ_01636     85.37       0.00          296
  CEP192                                                    hsa_circ_26363     84.76       0.00          307
  BMPR2                                                     hsa_circ_06837     81.99       0.00          503
  FGD4                                                      hsa_circ_21030     78.65       0.00          115
                                                                                                       

LPC Stimulation Disrupts the Expression Levels of 17 Spliceosome Components, Potentially Promoting Back Splicing for CircRNA Formation Over Canonical Splicing for mRNAs
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We and others reported that downregulation of certain spliceosome components promotes circRNA formation over canonical mRNA splicing ([@B89]; [@B107]); and that proinflammatory cytokine TNF-a, inflammation ([@B64]), autoimmune disease ([@B110]), and tumors modulate alternative splicing ([@B73]) and spliceosome ([@B113]). To determine whether this potential mechanism plays any roles in shaping LPC-modulated circRNA expression patterns, we compared the list of significantly changed mRNAs from RNA-Seq (determined via housekeeping gene confidence interval, as previously described) with lists of known spliceosome proteins ([@B23]; [@B115]; [@B11]; [@B12]; [Table 3](#T3){ref-type="table"}). Six spliceosome components were significantly downregulated after LPC stimulation, while another 11 were significantly upregulated. Given that 51 (66.2%) circRNAs were significantly upregulated while only 26 (33.8%) were significantly downregulated (*p* = 0.0029, where *p* represents the probability of a ratio equal to or more extreme than the experimental value, assuming circRNA upregulation and downregulation equally likely) and that among upregulated circRNAs, 10 corresponding mRNAs experienced significant downregulation while only 3 experienced significant upregulation (*p* = 0.0461, where *p* represents the probability of a ratio equal to or more extreme than the experimental value, assuming mRNA upregulation and downregulation equally likely) ([Figure 1A](#F1){ref-type="fig"} and [Table 3](#T3){ref-type="table"}), this disruption may have been sufficient to shift the splicing patterns from canonical mRNA splicing toward back splicing for circRNA formation ([Figure 3](#F3){ref-type="fig"}), as reported previously ([@B107]). While the data currently available is insufficient to establish a causal link between LPC-induced spliceosome disruption and a shift from canonical splicing to circRNA formation, it does demonstrate a strong association suitable for more intensive study. Taken together, our results suggest that LPC stimulation disrupts the expression levels of 17 spliceosome components, potentially promoting back splicing for circRNA formation over canonical splicing for mRNAs.

###### 

Seventeen spliceosome genes out of approximately 80 proteins have fold changes outside a housekeeping gene-determined 95 percent confidence interval in RNA-Seq data.

  Gene      FC
  --------- ------
  FUS       0.68
  PCBP2     0.68
  RBM7      0.77
  THOC1     0.82
  LSM8      0.83
  PCBP1     0.87
  RBM10     1.11
  EIF4A3    1.12
  CCDC130   1.12
  RBM42     1.13
  DGCR14    1.13
  MFAP1     1.18
  PUF60     1.18
  THOC3     1.20
  LSM6      1.21
  RNF113A   1.24
  FAM50B    1.25
            

There are 6 protein downregulation and 11 proteins upregulation.

![LPC modulates the expressions of spliceosome components and may facilitate the generation of circRNAs.](fphys-10-00433-g003){#F3}

Shifting Chromatin Long--Range Interaction Sites From Downstream to Upstream Is Associated With Induction of a List of Circular RNAs in LysoPC-Activated Human Aortic Endothelial Cells; and in Contrary, Shifting Chromatin Long--Range Interaction Sites From Upstream to Downstream Is Associated With Induction of a List of mRNAs
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Rapid development of technologies in capturing chromosome conformations such as chromosome conformation capture sequencing (3C-Seq) ([@B102]), chromosome conformation capture-on-chip (4C-Seq) ([@B24]; [@B91]), and chromosome conformation capture carbon copy sequencing (5C-Seq) ([@B92]) allows determination of the relative frequency of direct physical contact between a pair of linearly separated chromatin segments with 3C-Seq, and genome--wide interactions involving a single anchor region, and interactions involving multiple genomic regions with 4C-Seq and 5C-Seq, respectively ([Figure 4A](#F4){ref-type="fig"}). Differences in chromatin long-range interaction patterns between genes have previously been hypothesized to influence alternative splicing ([@B27]) and the transcription of inflammatory genes such as cytokine ([@B2]) and cytokine receptor ([@B76]) and cardiovascular disease causative genes ([@B25]). We hypothesize that chromatin long--range interactions differentially regulate the gene promoters to differentiate the mRNA increase from circRNA increase versus decrease, derived from the same gene, under LPC stimulation in HAECs. To test this hypothesis with respect to circRNA biogenesis, we obtained long-range interaction data for all genes related to significantly changed circRNAs from the well-accepted 4DGenome database with a huge collection of 4,433,071 experimentally derived chromatin long--range interactions ([@B97]). We then calculated the distances between interacting genes with respect to the circRNA-related gene, with distances designated as positive if the circRNA-related gene was localized downstream of its partner and as negative if the circRNA-related gene was localized upstream of its partner. The two-sample Kolmogorov--Smirnov test of the chromatin long-range interaction distance between genes corresponding to downregulated and upregulated circRNAs indicated a significant difference between the two distance distributions (*p* \< 0.001). *First*, the majority of long-range interaction sites with circRNA-related genes were focused on 10^6^ kb upstream and downstream of the circRNA-related gene, suggesting a common feature of the long-range chromatin interaction sites with LPC-induced circRNA-related genes; *Second*, in the three groups with circRNA related genes such as (a) upregulation; (b) downregulation; or (c) no changes induced by LPC, the group with LPC-induced upregulation of mRNAs had the lowest peak, the group with LPC-induced downregulation of mRNAs had the middle peak, the group with LPC-induced no changed expression of mRNAs had the highest peak, suggesting that high concentration of chromatin long-range interaction sites prevents HAECs from responding to LPC stimulation in changing gene expressions ([Figure 4B,C](#F4){ref-type="fig"}); *Third*, in both groups of mRNA upregulation and mRNA downregulation induced by LPC, circRNA increase was associated with increased upstream chromatin long-range interaction sites, suggesting that an increase in upstream chromatin long-range interaction sites is associated with circRNA generation presumably by favoring back-splicing in generating circRNAs over canonical splicing in generating mRNAs ([Figure 4C](#F4){ref-type="fig"}). In contrast, a decrease in upstream chromatin long-range interaction sites is associated with mRNA generation presumably by favoring canonical splicing in generating mRNAs over back-splicing in generating circRNAs ([Figure 4C](#F4){ref-type="fig"}). Altogether, these results suggest that different long-range interaction mechanisms are likely to govern circRNA upregulation and downregulation. Indeed, upregulated circRNAs tended to interact at somewhat longer distances than downregulated circRNAs did ([Figure 4B,C](#F4){ref-type="fig"}). Since the 4DGenome database contains the experimental data derived from human non-aortic ECs ([@B97]), the future work will be needed to use circular chromosome conformation capture sequencing (4C-Seq) to examine HAECs stimulated with LPC to map the specific upstream interaction sites for a favorable selection of circRNA over mRNAs. Therefore, our results may suggest that certain ideal long-range interaction distances exist that are more likely to promote circularization; and that favorable distances tend to be greater in magnitude than unfavorable ones.

![**(A)** Chromatin long range interaction may regulate the expressions of circRNAs-related genes via forming chromatin loops. **(B)** Loosely packed chromatin regions either upstream or downstream from circRNAs related gene promoters may differentially prefer back splicing to generate circRNAs to canonical splicing to generate mRNAs. **(C)** Shifting chromatin long-range interaction sites from downstream to upstream may promotes a list of circular RNAs; and in contrast, shifting chromatin long-range interaction sites from upstream to downstream promotes induction of a list of mRNAs. The data were collected from the experimental data deposited in the 4DGenome database (<https://4dgenome.research.chop.edu>) containing the data from human umbilical vein endothelial cells (HUVECs).](fphys-10-00433-g004){#F4}

Six Significantly Changed CircRNAs Sponge miRNAs, Which May Be Associated With Inhibition of Type 2 Diabetes Mellitus, Inhibition of Migration, and Inhibition of Vascular Dysfunction and Immune Responses in Endothelial Cells
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A number of circRNAs can sponge miRNAs, preventing miRNA-mediated degradation of mRNA transcripts and disruption of canonical signaling and effector pathways ([@B37]; [@B69]). Thus, by regulating miRNA activity, significantly changed circRNAs can act through canonical pathways, potentially playing a significant role in HAEC activation. We examined the sponging potential of all significantly changed circRNAs using the CircInteractome database ([@B71]), recording two miRNAs with four or more predicted binding sites in a single circRNA transcript, a threshold above which meaningful sponging activity is likely to occur [@B69]. Another four significantly changed circRNAs are experimentally shown to sponge miRNAs ([@B30]; [@B19]; [@B112]; [@B105]), for six total circRNAs with miRNA sponging activity including miR125, miR143, miR1272, miR153, miR515-5p, and miR196a-5p ([Table 4](#T4){ref-type="table"}). In [Figure 5A](#F5){ref-type="fig"}, to demonstrate the proof of principle, we showed how circRNA has_circ_30156 could inhibit type 2 diabetes mellitus (T2DM) by sponging miR143 and preventing miR143 from binding to oxysterol-binding protein-related protein 8 (ORP8) 3′untranslated region (3′UTR).

###### 

Six circRNAs demonstrate miRNA sponging activities.

  Gene    circRNAdb ID     miRNA sponged   Readnumber (LPC)   Readnumber (control)   Ratio   Function of microRNA                     PMID
  ------- ---------------- --------------- ------------------ ---------------------- ------- ---------------------------------------- ----------
  PVT1    hsa_circ_16350   miR-125           8                  1                      8     Promote regeneration/repair              29461585
  UBAP2   hsa_circ_30156   miR-143           1                  7                    0.14    Inhibit autophage/promote inflammation   29562274
  VAMP3   hsa_circ_18051   miR-1272          7                  1                      7     T cell differentiation                   26941729
  VRK1    hsa_circ_08594   miR-153           4                  1                      4     Inhibit migration/invasion               29113423
  FGD4    hsa_circ_21030   miR-515-5p        1                  9                    0.11    Decrease in atopic eczema                17622355
  DOCK1   hsa_circ_00689   miR-196a-5p       7                  1                      7     Delay lymph node metastasis              29434944
                                                                                                                                      

![**(A)** CircRNA has the potential role to inhibit type 2 diabetes mellitus (T2DM)by sponging miRl43 and preventing miRl43 from binding to oxysterol-binding protein-related protein 8 (ORP8) ˆuntranslated region (3′UTR). **(B)** Upregulated circRNAs sponge miRNAs involved in both pro- and anti-inflammatory pathways. **(C)** Downregulated circRNAs sponge miRNAs are involved with both pro-inflammatory and anti-inflammatory pathways. **(D)** One pathway is overlapped in the sponged microRNAs between upregulated and downregulated circRNAs.](fphys-10-00433-g005){#F5}

To elucidate potential downstream pathways for these miRNAs that might influence the LPC-induced inflammatory response, we separately performed IPA for miRNAs sponged by upregulated and downregulated circRNAs, respectively. Notably, the top two pathways for miRNAs sponged by upregulated circRNAs were the pro-inflammatory type 1 T helper cell (Th1), and Th2 activation pathway, and the anti-inflammatory glucocorticoid receptor signaling pathway ([Figure 5B](#F5){ref-type="fig"}). Similarly, miRNAs sponged by downregulated circRNAs were prominently implicated in the anti-inflammatory transforming growth factor-β (TGF-β) signaling pathway and the pro-inflammatory interleukin-12 (IL-12) signaling and production in macrophages pathway ([Figure 5C](#F5){ref-type="fig"}). Owing to these numerous conflicting results, the pro- and anti-inflammatory effects of the predicted downstream pathways likely cancel in large part, resulting in little overall pro- or anti-inflammatory effects ([Figure 5D](#F5){ref-type="fig"}). Specifically, microRNA-125a plays crucial roles both in development and in the adult tissues, including it: (1) contributes to the control of phase transitions in development and/or cell differentiation; (2) regulates the expression of several target proteins that are involved in cell proliferation, apoptosis, and migration; (3) interferes with the expression of the hepatitis B virus surface antigen in liver cells, thus counteracting viral replication ([@B121]). miR-125b plays a significant role in immune response and apoptosis ([@B81]). The novel long intergenic non-coding RNA UCC promotes colorectal cancer progression by sponging miR-143 ([@B82]). The function of miR1272 remains unreported. miR153 is tumor suppressive ([@B42]), and miR153 targeting of KCNQ4 contributes to vascular dysfunction in hypertension ([@B123]). miR-515-5p controls cancer cell migration through MARK4 regulation ([@B17]). Higher expression of miR-196a was both associated with poor overall survival and disease-free survival and recurrence-free survival in different kinds of cancers ([@B75]). Taken together, sponging of most of six miRs in ECs may be associated with inhibition of migration, inhibition of vascular dysfunction and immune responses.

74% Significantly Changed CircRNAs Contain Open Reading Frames, the Majority of Which Encode Fragments of Known Proteins
------------------------------------------------------------------------------------------------------------------------

Despite their classification as ncRNAs, numerous circRNAs can be translated into peptides, some of which are novel forms with uncharacterized yet potentially relevant function ([@B14]; [@B55]; [@B74]). Moreover, the circRNAdb database used to assign circRNA IDs provides ORF peptide sequence data for all circRNAs with ORFs ([@B20]). To assess the potential of significantly changed circRNAs to encode small proteins/peptides, we performed NIH NCBI BLAST peptide sequence alignments against the NCBI non-redundant protein sequences database (nr), restricted to entries for *Homo sapiens*, for all significantly changed circRNAs with ORF data in circRNAdb using the NIH NCBI BLAST+ command line utility (blastp -db nr -remote -entrez_query "Homo sapiens \[Organism\]" -max_target_seqs 1 -outfmt "10 sacc pident *e*-Value") ([Table 5A](#T5a){ref-type="table"}). Out of 77 significantly changed circRNAs, 57 (74.0%) contained ORFs; of these, 48 ORF peptide sequences matched substantially (with an expected value \< 1^∗^10^-4^) to fragments of known proteins. Notably, 47 of the 48 ORFs with substantial matches mapped to a protein encoded by mRNA corresponding to the same gene as the circRNA, the sole exception originating from a circRNA corresponding to the non-coding gene PVT1. A majority of significantly changed circRNAs, therefore, have protein-coding potential and could produce fragments of known proteins. Such protein fragments remain both uncharacterized and experimentally undetected, but could theoretically serve physiological functions, including ones different from those of the full canonical protein ([Figure 6](#F6){ref-type="fig"}). Furthermore, using predicted IRES data from circRNAdb, we found that all 57 circRNAs with ORFs contain at least one predicted IRES, and 32 of them (56.1%) contain at least one predicted IRES with an *R*-value (a metric indicating suitability of a sequence as an IRES) greater than a previously determined cutoff value of 1.54 and a predicted pseudoknot structure, which together indicate a greater probability of ribosomal entry and subsequent translation ([@B116]). We previously reported that this type of IRES drive secondary open reading frames is translated into short proteins ([@B108]); and that short peptides can disrupt the protein--protein interactions ([@B109]). The Kozak consensus sequence is a sequence which occurs on eukaryotic mRNA and has the consensus (gcc) gccRccAUGG, which plays a major role in the initiation of the translation process ([@B117]). However, NIH NCBI BLAST searches for [@B52] sequences insignificantly changed circRNAs did not yield any matches.

###### 

All but one circRNA open reading frames with significant BLAST matches encode peptides from the same gene as their corresponding mRNAs.

  Gene                                        circRNAdb ID     Accession      \% ID    *E*-value   Same translation as mRNA?
  ------------------------------------------- ---------------- -------------- -------- ----------- -----------------------------
  Near-perfect overlap with known sequences                                                        
  VAMP3                                       hsa_circ_18051   XP_016858330   100      0.00        Yes
  DOCK1                                       hsa_circ_00689   Q14185         100      0.00        Yes
  HNRNPM                                      hsa_circ_20744   BAG57075       100      0.00        Yes
  FOXP1                                       hsa_circ_19469   BAC11065       100      0.00        Yes
  TBC1D8                                      hsa_circ_32540   BAA76517       100      0.00        Yes
  KANSL1L                                     hsa_circ_06859   XP_011509011   100      0.00        Yes
  RUNX1T1                                     hsa_circ_02162   AAB34820       100      0.00        Yes
  CSNK1G3                                     hsa_circ_08140   XP_016864559   100      0.00        Yes
  TPST1                                       hsa_circ_22617   XP_011514936   100      0.00        Yes
  RCAN3                                       hsa_circ_22201   NP_001238914   100      0.00        Yes
  NEIL3                                       hsa_circ_00262   Q8TAT5         100      0.00        Yes
  PPP6R2                                      hsa_circ_07544   EAW73534       100      0.00        Yes
  VRK1                                        hsa_circ_08594   2LAV_A         100      0.00        Yes
  BABAM1                                      hsa_circ_04303   BAG61451       100      0.00        Yes
  RYK                                         hsa_circ_26048   AAH21700       100      0.00        Yes
  ATXN1                                       hsa_circ_13397   NP_000323      100      0.00        Yes
  ACVR2A                                      hsa_circ_04751   AAH67417       100      0.00        Yes
  PRKY                                        hsa_circ_30664   O43930         100      0.00        Yes
  UBAP2                                       hsa_circ_30156   BAG64527       100      0.00        Yes
  RELL1                                       hsa_circ_08846   XP_016864079   100      0.00        Yes
  NFAT5                                       hsa_circ_16704   XP_016878362   100      0.00        Yes
  CEP192                                      hsa_circ_26363   XP_016881293   100      0.00        Yes
  SDF4                                        hsa_circ_21644   XP_011539858   100      0.00        Yes
  CORO1C                                      hsa_circ_01619   BAH14436       100      0.00        Yes
  ADAMTS6                                     hsa_circ_28538   XP_011541429   100      0.00        Yes
  ASAP1                                       hsa_circ_09642   CAD97831       100      0.00        Yes
  MAN1A2                                      hsa_circ_02643   XP_016855604   100      0.00        Yes
  ANKRD17                                     hsa_circ_01636   XP_016863500   99.796   0.00        Yes
  ANKRD12                                     hsa_circ_31497   BAB15014       99.683   0.00        Yes
  CRIM1                                       hsa_circ_16396   XP_016859748   99.448   0.00        Yes
  PSD3                                        hsa_circ_02851   XP_016868754   99.333   0.00        Yes
  PDS5B                                       hsa_circ_01546   AAH70274       99.048   0.00        Yes
  FNDC3B                                      hsa_circ_15231   EAW78473       98.864   0.00        Yes
  FUT8                                        hsa_circ_02544   BAA92858       98.551   0.00        Yes
  PCNXL2                                      hsa_circ_10712   BAG51507       98.387   0.00        Yes
  RHOBTB3                                     hsa_circ_19124   EAW96050       98.148   0.00        Yes
  PTK2                                        hsa_circ_23485   NP_001339677   98.052   0.00        Yes
  SCAP                                        hsa_circ_19380   EAW64826       97.5     0.00        Yes
  EPHB4                                       hsa_circ_08510   4AW5_A         97.5     0.00        Yes
  IQGAP1                                      hsa_circ_10932   AAH05906       97.458   0.00        Yes
  XXYLT1                                      hsa_circ_02143   XP_005269343   97.403   0.00        Yes
  SMURF2                                      hsa_circ_01208   EAW94194       97.03    0.00        Yes
  CNTROB                                      hsa_circ_09218   XP_016879630   97.015   0.00        Yes
  LZIC                                        hsa_circ_31394   NP_001303904   96.97    0.00        Yes
  TTC28                                       hsa_circ_22261   XP_011528324   96.947   0.00        Yes
  PVT1                                        hsa_circ_16350   EAW92103       95.918   0.00        No (non-coding gene)
  FAM13B                                      hsa_circ_11413   XP_016865040   87.786   0.00        Yes
  N4BP2L2                                     hsa_circ_12240   EAX08513       78.261   0.00        Yes (fragment of same gene)
  Partial overlap with known sequences                                                             
  BMPR2                                       hsa_circ_06837   NP_057675      56       3.10        
  ESYT2                                       hsa_circ_25060   EAW95833       48       3.20        
  GRHPR                                       hsa_circ_03935   EAW60274       39.286   3.00        
  No overlap with known sequences                                                                  
  RNF38                                       hsa_circ_32756                                       
  SIPA1L3                                     hsa_circ_10577                                       
  SCAF8                                       hsa_circ_06913                                       
  CDK8                                        hsa_circ_27078                                       
  ECSIT                                       hsa_circ_00599                                       
  FGD4                                        hsa_circ_21030                                       
                                                                                                   

![One example of potential disruption of protein--protein interactions by circRNA encoded short peptides is demonstrated.](fphys-10-00433-g006){#F6}

We previously reported that short peptides with high homology to the interaction domain sequences of protein interaction partners could interfere the protein interaction ([@B117]). To demonstrate the proof of principle, in [Figure 6](#F6){ref-type="fig"}, as suggested by the experimental data in the NIH-NCBI-Gene database^[9](#fn09){ref-type="fn"}^, focal adhesion kinase 1 (PTK2) has as many as 225 interaction proteins ([Table 5B](#T5b){ref-type="table"} and Figure 6), thus, the circRNA hsa_circ_23485 encoded short peptide(s) could disrupt the protein interaction between PTK2 and interaction proteins. Taken together, 74% significantly changed circRNAs contain open reading frames, the majority of which encode fragments of known proteins, which may interfere with protein interaction-based signaling pathways. Of note, in addition to perform experiments in the future to verify the circRNAs, we also notice that various novel computational methods for finding ncRNAs versus coding RNAs ([@B1]) and identifying small peptides ([@B77]) have been developed, so that we will collaborate in the future with bioinformatics experts to verify the generation of those potential short peptides in HAECs.

###### 

75 of 77 circRNA-related genes have numerous interactions with other proteins, suggesting that functional interactions between the circRNAs-related proteins and their interaction proteins may be disrupted by circRNA-encoded short peptides.

  Gene name       circRNAdb ID     Interactions
  --------------- ---------------- --------------
  TEX2            hsa_circ_31354       7
  MYO9A           N/A                27
  PVT1            hsa_circ_16350       2
  CRIM1           hsa_circ_16396       3
  VAMP3           hsa_circ_18051     74
  DOCK1           hsa_circ_00689     37
  SCAP            hsa_circ_19380     29
  HNRNPM          hsa_circ_20744   341
  GRHPR           hsa_circ_03935     34
  FOXP1           hsa_circ_19469     47
  RP11-146B14.1   N/A              N/A
  RNF38           hsa_circ_32756     17
  SMURF2          hsa_circ_01208   201
  ARFGEF2         N/A                53
  RNF138          hsa_circ_01057     45
  TTC28           hsa_circ_22261     25
  LZIC            hsa_circ_31394     13
  L3MBTL3         N/A                38
  TBC1D8          hsa_circ_32540       6
  KANSL1L         hsa_circ_06859       0
  RUNX1T1         hsa_circ_02162     96
  CSNK1G3         hsa_circ_08140     38
  SIPA1L3         hsa_circ_10577     39
  TPST1           hsa_circ_22617     13
  MACF1           N/A                85
  RCAN3           hsa_circ_22201     14
  UGGT1           N/A                65
  PARD3B          N/A                  7
  NEIL3           hsa_circ_00262     19
  CNTROB          hsa_circ_09218   123
  SLF2            N/A                  9
  PDS5B           hsa_circ_01546     54
  CUX1            hsa_circ_12403     69
  DNAAF5          N/A                66
  IQGAP1          hsa_circ_10932   294
  PPP6R2          hsa_circ_07544     69
  VRK1            hsa_circ_08594     34
  PDS5A           hsa_circ_29001     76
  BABAM1          hsa_circ_04303     67
  FAM213A         N/A                23
  EVI5            hsa_circ_11187     18
  SCAF8           hsa_circ_06913     22
  RYK             hsa_circ_26048     93
  FIP1L1          hsa_circ_18069     81
  CDK8            hsa_circ_27078   120
  ATXN1           hsa_circ_13397   416
  ACVR2A          hsa_circ_04751     48
  ECSIT           hsa_circ_00599   117
  XXYLT1          hsa_circ_02143     10
  PRKY            hsa_circ_30664       8
  PCNXL2          hsa_circ_10712       3
  ANKRD12         hsa_circ_31497     17
  BMPR2           hsa_circ_06837     99
  N4BP2L2         hsa_circ_12240     29
  UBAP2           hsa_circ_30156     34
  PSD3            hsa_circ_02851       8
  FUT8            hsa_circ_02544     30
  RELL1           hsa_circ_08846     19
  TBCD            hsa_circ_00754     64
  PTK2            hsa_circ_23485   225
  NFAT5           hsa_circ_16704     10
  FGD4            hsa_circ_21030       5
  CEP192          hsa_circ_26363     78
  SDF4            hsa_circ_21644     92
  ANKRD17         hsa_circ_01636     40
  CORO1C          hsa_circ_01619   109
  RARS            hsa_circ_21209   146
  ADAMTS6         hsa_circ_28538       2
  SCMH1           hsa_circ_12377     41
  FAM13B          hsa_circ_11413       6
  EPHB4           hsa_circ_08510     30
  ESYT2           hsa_circ_25060     34
  ASPH            hsa_circ_10828     44
  FNDC3B          hsa_circ_15231     12
  ASAP1           hsa_circ_09642     44
  MAN1A2          hsa_circ_02643     17
  RHOBTB3         hsa_circ_19124     35
                                   

Discussion
==========

We previously published experimental data outlining the role of LysoPC (LPC) on HAEC (Li et al., 2018c). In this previous publication we demonstrated that LysoPC stimulation leads to: (1) the upregulation of inflammatory adhesion molecules in HAEC; (2) upregulation of cytokine transcript expression; and (3) promotion of prolonged HAEC activation and expression of innate immune co-stimulation molecule expression. We believe that this RNA-Seq (RNA sequencing) data analyses provide strong experimental evidence for the role of LysoPC stimulation of proinflammatory mRNAs. Given that alternative splicing events lead to the generation of circRNAs from mRNA precursors in other cell types ([@B107]), there is strong justification to explore the role of LysoPC-induced circRNAs.

Although the importance of circRNAs in regulating EC function has been reported, the comprehensive analyses of circRNAs in EC activation, EC function, and cardiovascular diseases remain at their infancy; and the characterization of circRNAs in atherosclerosis-relevant HAECs has not been reported ([@B66]; [@B43]; [@B85]). To fill in this important knowledge gap, we profiled the circRNAs in HAECs stimulated with we proposed "conditional danger associated molecular pattern" LPC ([@B104]), and compared the circRNAs significantly modulated in HAECs by LPC with the mRNAs modulated in the same sets of RNA-Seq samples ([@B60]).

In the current study, we made the following findings: *first*, LPC modulates the expression of a list of 77 circRNAs in HAECs; and the majority of which, 94.1% of increased circRNAs, compete with related mRNAs for exon usage; *second*, circRNAs-related genes do not share any top pathways with LPC-induced mRNA pathways, and genes associated with significantly changed circRNAs exhibit little relationship with potential effects of inflammation-related cytokine stimulation; *third*, 68.8% of the circRNAs feature significant flanking intron homology; *fourth*, LPC stimulation disrupts the expression levels of 17 spliceosome components, potentially promoting back splicing for circRNA formation over canonical splicing for mRNAs; *fifth*, shifting chromatin long-range interaction sites from downstream to upstream promotes induction of a list of circRNAs in lysoPC-activated HAECs; and in contrary, shifting chromatin long-range interaction sites from upstream to downstream promotes induction of a list of mRNAs; *sixth*, six significantly changed circRNAs sponge miRNAs, which may be associated with inhibition of type 2 diabetes mellitus, inhibition of migration, inhibition of vascular dysfunction and immune responses in ECs; and *seventh*, 74% significantly changed circRNAs contain open reading frames, the majority of which encode fragments of known proteins, suggesting that short proteins generated from the secondary open reading frames potentially driven by internal ribosome entry sites may interfere the protein-protein interaction-based signaling.

As reported previously, LPC stimulation causes significant changes in mRNA expression levels for many genes ([@B60]). IPA of these changed genes implicates several common upstream regulatory signaling pathways, the most significant of which are the sterol regulatory element binding transcription factor 2 (SREBF2), SREBF chaperone (SCAP), and SREBF1 pathways (not shown), which jointly serve as key lipid metabolism regulators and contribute to pro-inflammatory signaling ([@B86]). This establishes a novel association between upregulated pro-inflammatory lipid metabolism pathways and significant expression changes for 77 circRNAs. Our data are insufficient to conclude any roles of lipid metabolism pathways in circRNA expression modulation. However, given the strength of the association between the significantly changed upstream pathways and the significantly changed circRNAs, more direct future investigation of the effects of lipid metabolism pathway disruption on circRNA levels will be appropriate and could confirm or extend this observation.

It is highly unlikely that the extreme ratio of upregulated to downregulated circRNAs or that of upregulated to downregulated corresponding mRNAs among upregulated circRNAs under LPC stimulation would occur by chance, as noted earlier. For this reason, spliceosome depletion, which is experimentally demonstrated to cause such responses in circRNA and mRNA expression ([@B64]; [@B107]), continues to be a compelling area for future study despite the inconclusive results presented in this study. For instance, knockdown of downregulated or overexpression of upregulated spliceosome components identified after LPC stimulation, potentially combined with more robust circRNA detection methods such as qPCR verification of back-spliced sequences ([@B45]; [@B93]), could clarify the role of each component in LPC-induced disruption of circRNA expression patterns.

Additionally, the dramatic expression changes of many circRNAs under LPC stimulation suggests that they play currently undetermined, possibly significant roles in HAEC activation and the proatherogenic response. Indeed, the circRNA *circular antisense non-coding RNA in the INK4 locus* (circANRIL) performs anti-atherogenic, anti-proliferative functions *in vitro* by inhibiting ribosomal biogenesis through assembly factor binding ([@B40]), although this circRNA was not detected in our data set. Nevertheless, it is possible that some significantly changed circRNAs fulfill regulatory roles in atherogenesis through similar mechanisms. As circRNAs are better characterized and prediction of RNA-protein binding becomes more sophisticated, it may be possible to detect protein-binding functions, including those related to atherogenesis or atheroprotection, in our significantly changed circRNAs.

Likewise, many of our significantly changed circRNAs could encode proteins. Although the ORFs detected match the loci of canonically spliced mRNAs, many of the peptides encoded are likely to be fragments of canonical proteins and therefore may serve different functions. Knock-in experiments of these novel predicted peptides could uncover new insights about their potential roles in LPC-induced atherogenesis. Furthermore, as our current findings do not include protein expression data, additional assay experiments under LPC stimulation, such as Western blots and high-performance liquid chromatography-linked mass spectrometer analyses specific to these novel predicted peptides, would provide additional insight on their expression patterns. Given the established coding potential of circRNAs ([@B55]; [@B74]; [@B116], such microproteins remain an underexplored pathway for circRNA regulatory roles in atherogenesis.

Furthermore, the field of circRNAs is still in its infancy. Software detection methods may give widely differing results, and not all circRNAs predicted from RNA-Seq data can be verified experimentally through methods such as RNase R-catalyzed degradation ([@B38]). Simply repeating an LPC-induced HAEC activation experiment, treating with RNase R to remove spurious linear transcripts, and using additional circRNA algorithms to corroborate findings could provide more accurate data on circRNA expression change; using qPCR confirmation for particularly meaningful or significant detections would likewise further improve data reliability. Additionally, recent studies have outlined a number of novel experimental methods for verifying the expression and function ([@B45]; [@B78]; [@B9]; [@B106]; [@B65]; [@B120]; [@B36]; [@B60]). Overall, however, changes in circRNA expression levels following LPC stimulation follow unusual and poorly understood patterns, and further, more intensive profiling under otherwise identical conditions could reveal regulatory pathways not apparent in this study, which uses relatively simple detection methods. To this end, future studies are required using clinical arterial samples from atherosclerotic patients and healthy controls through the collaboration with vascular surgeons using the Temple University Institutional Review Board approved protocol.

Taken together, based on our findings, we propose a novel working model ([Figure 7](#F7){ref-type="fig"}): *first*, modulation of 77 significantly changed circRNAs in LPC-activated HAECs is temporally associated with LPC-upregulated cholesterol synthesis-SREBP2 pathway and LPC-downregulated TGF-β pathway that we reported recently ([@B60]); *second*, the generation of circRNAs in LPC-activated HAECs may be facilitated by three novel molecular mechanisms including: (i) high flanking intron homologies, (ii) LPC-induced modulation of spliceosome components, and (iii) increased upstream chromatin long--range interactions; and *third*, circRNAs in LPC-activated HAECs may play homeostatic functions by acting on a few novel aspects, including: S (a) competition with related mRNAs for exon usage, (b) miRNA sponge, and (c) secondary open reading frame-generated short peptide disruption of protein-protein interaction. We acknowledge that circRNAs profiling data have brought a huge amount of new findings for detailed experimental verifications in the future. Nevertheless, these novel insights may lead to identification of new therapeutic targets for treating metabolic cardiovascular diseases, inflammations, and cancers.

![A new working model: Proatherogenic lipid, LPC, induces the upregulation of a group of circular RNAs in human aortic endothelial cells, which may be generated by three mechanisms and play homeostatic functions via three effector mechanisms.](fphys-10-00433-g007){#F7}
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